Lakewood-Amedex Biotherapeutics Inc. SEC filings LABT

Lakewood-Amedex Biotherapeutics Inc. has 44 filings in SEC EDGAR's recent list, going back to Jul 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 29, 2026 (shareholder vote results). The company's fiscal year ends on December 31.

Lakewood-Amedex Biotherapeutics Inc. SEC filings
Form Description Filed Period
EFFECT Filing Sep 24, 2026 —
DRS Filing Aug 24, 2026 —
EFFECT Filing May 13, 2026 —
CORRESP Letter to the SEC May 12, 2026 —
UPLOAD Letter from the SEC May 8, 2026 —
CERT Filing Apr 22, 2026 —
EFFECT Filing Apr 17, 2026 —
8-A12B For registration of certain classes Apr 17, 2026 —
DRS/A Filing Oct 17, 2025 —
DRS Filing Jul 31, 2025 —

Showing 10 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
LABT (Nasdaq)
Fiscal year ends
December 31
Incorporated in
NV
Headquarters
University Park, FL
SEC filer status
, Emerging growth company
SEC CIK
2079272

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.